Select Page

HICSIG VRE survey (short) focused on vanA VRE epidemiology

Home Forums Infexion Connexion HICSIG VRE survey (short) focused on vanA VRE epidemiology

 | Click to Receive Email Notifications of Posts
Viewing 1 post (of 1 total)
  • Author
    Posts
  • #72778
    John Ferguson
    Participant

    Author:
    John Ferguson

    Email:
    John.Ferguson@HNEHEALTH.NSW.GOV.AU

    Organisation:

    State:

    Dear All

    Please excuse this cross-posting. Perhaps our infection prevention colleagues can provide information please relating to their sites? http://freeonlinesurveys.com/s/gVBo3a6G

    Thanks
    John

    From: John Ferguson
    Sent: Wednesday, 17 February 2016 12:50 PM
    To: asid-ozbug@malbec.burnet.edu.au
    Subject: HICSIG VRE survey (short) focused on vanA VRE epidemiology

    Dear All,

    http://freeonlinesurveys.com/s/gVBo3a6G

    The 2014 AGAR VRE data (unpublished as yet) indicates two prominent pulsotypes of vanA across Australia 20 of 35 reported BSI events were

    either Efm18 or Efm85. 2015 isolates not typed yet due to delay in funding sequencing planned. According to Geoff Coombs, Efm85 is also now the predominant vanA type in WA in 2015 with more vanA detected there than vanB now. Prior to 2-3 years ago, the sporadic vanA recorded was polyclonal in WA.

    Whilst a majority of our vanA appears to be healthcare associated, we have been struck by the simultaneous emergence of two predominant pulsotypes across the country from 2013/14 onwards. As yet there is limited published sequence data on vanA in Australia/NZ that we aware of ( Victoria is currently sequencing all isolates from last November and AGAR isolate sequencing planned). If indeed, largely clonal vanA has been emerging in a multicentric way across ANZ, then this may not just reflect a healthcare problem (remembering the zoonotic origins of vanA VRE in Europe way back when) .

    This survey aims to gauge how much VRE is being seen across the country. The results will be presented in Paul Johnsons presentation at the next ASID Scientific Meeting. We are also interested to learn about whether folk have stopped trying to manage vanB VRE cases under Contact Precautions (as has been successfully done at the Alfred for instance).

    Thanks in anticipation: the survey is short but will require some knowledge of your local VRE isolate history and laboratory process in terms of numbers of patient isolates etc. so please do speak with your micro people!

    Kind regards,

    Eugene Athan (Chair, HICSIG)

    John Ferguson (Hunter New England Health)

    Dr John Ferguson MBBS DTM&H FRACP FRCPA
    Microbiologist | Pathology North, NSW Pathology
    Infectious Diseases Physician | Immunology and Infectious Diseases Unit
    John Hunter Hospital, Locked Bag 1, Newcastle Mail Centre, NSW 2310, Australia
    T: 61 2 49214444 | F: 61 2 49214440 | M: +61(0)428 885573 (Speed Dial 67607) | Tw @mdjkf
    Follow http://www.aimed.net.au, the HNE Health/Pathology North site for practical discussions about antibiotic use.

    [cid:image001.jpg@01D16981.BE859C20]

    MESSAGES POSTED TO THIS LIST ARE SOLELY THE OPINION OF THE AUTHOR, AND DO NOT REPRESENT THE OPINION OF ACIPC.

    The use of trade/product/commercial brand names through the list is discouraged by ACIPC. If you wish to discuss specific reference to products or services by brand or commercial names, please do this outside the list.

    Archive of all messages are available at http://aicalist.org.au/archives – registration and login required.

    Replies to this message will be directed back to the list. To create a new message send an email to aicalist@aicalist.org.au

    To send a message to the list administrator send an email to aicalist-request@aicalist.org.au.

    You can unsubscribe from this list be sending ‘signoff aicalist’ (without the quote

Viewing 1 post (of 1 total)
  • The forum ‘Infexion Connexion’ is closed to new topics and replies.